Ironwood (IRWD) 2025 Financial Guidance. Ironwood continues to expect: 2025 Guidance: Sees U.S. LINZESS net sales $800 – $850M; High single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign SeesTotal Revenue $260 – $290M;Sees FY 25 adjusted EBITDA $85M +…
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood reports Q4 EPS 2c, consensus 8c
- Ironwood Pharmaceuticals (IRWD) Q4 Earnings Cheat Sheet
- Millrose Properties to replace Ironwood in S&P 600 at open on 2/10
- Ironwood price target lowered to $7 from $12 at Wells Fargo
- American Air flight crashes in D.C., Microsoft reports Q2 beat: Morning Buzz